Correction to: Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel Na_V1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers

Affiliations

¹ Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. rothenberg.michael@gene.com.
² Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.

Published Erratum

Michael E Rothenberg et al. Clin Drug Investig. 2019 Sep.

. 2019 Sep;39(9):889-890.

doi: 10.1007/s40261-019-00832-2.

¹ Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. rothenberg.michael@gene.com.
² Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.

Abstract

The original version of this article unfortunately contained a mistake. A few entries were incorrect in Table 2.

Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel Na_V1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers.
Rothenberg ME, Tagen M, Chang JH, Boyce-Rustay J, Friesenhahn M, Hackos DH, Hains A, Sutherlin D, Ward M, Cho W. Rothenberg ME, et al. Clin Drug Investig. 2019 Sep;39(9):873-887. doi: 10.1007/s40261-019-00807-3. Clin Drug Investig. 2019. PMID: 31172446 Clinical Trial.